
Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t

Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w

Christian Manegold Nick Thatcher Christian Manegold, Heidelberg University Medical Center, Manheim Nick Thatcher, Christie Hospital, Manchester Is bevacizumab a new standard of care for patients with

Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of Hematology Annual Meeting (December 8-11, 2007

Volume 16 Number 5 (March 1st, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando) A

Timothy Illidge Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 TIMOTHY ILLIDGE, Christie Hospital, Manchester Radioconjugated antibodies are showing grea

Bart Barlogie Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 BART BARLOGIE, University of Arkansas, Little Rock A treatment known as “total therapy

Kenneth Anderson Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston Multiple myeloma may soon be consi

David Cunningham REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 DAVID CUNNINGHAM, Royal Marsden Hospital, London The oral agent capeticabine

Michel Coleman Michel Coleman (London School of Hygiene and Tropical Medicine) explains how cancer will become a new priority in the EU.

Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro

Robert Mayer ROBERT MAYER, Dana-Farber Cancer Institute, Boston One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some